DBVT Stock — DBV Technologies S.A.: Cash, EV, Pipeline

Share price

$12.35

Market cap

$730.9M

Cash

$174.9M

Enterprise value

$556.0M

Balance sheet

Cash	$174.9M
Debt	$0.0M
Net cash	$174.9M
Enterprise value	$556.0M
Basic shares	433.5M shares
Fully diluted shares	551.1M shares
Fully diluted market cap	$6,806.0M
Cash per share	$0.40

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading DBVT daily closes…

Loading price history…

Pipeline assets

Viaskin Peanut

Phase 3 · Active Modality: epicutaneous immunotherapy (EPIT) patch

Partnerships Sanofi: API manufacturing; FAREVA: patch manufacturing

Indications

Peanut allergy (toddlers 1-3 years) (Phase 3)
Peanut allergy (children 4-11 years) (Phase 3)

Status note Toddlers program (pivotal Phase 3; COMFORT Toddlers supplemental safety study screening since Jun 2025; EPOPEX open-label extension) intended to support a future BLA. Children 4-11: VITESSE Phase 3 positive topline announced Dec 16, 2025. No approved treatment for peanut-allergic children under 4.

Per-asset detail extracted from the 10-Q filed 2026-07-16. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	1,461,425	no change	0.12%	2026-08-14
Logos Global Management	915,000	+915,000	0.65%	2026-08-14
ADAR1 Capital Management	528,295	-484,571	0.41%	2026-08-14
Ikarian Capital	525,000	no change	0.28%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

DBVT — DBV Technologies S.A.

Balance sheet

Price history

Pipeline assets

Institutional holders